mann, tankefull.jpg

Urinlekkasje hos menn

Urinlekkasje

Pasientinformasjon

Nyrer og urinveier

Kliniske kapitler

Håndboken

Norsk Elektronisk Legehåndbok

Hva er urininkontinens hos menn?

Årsaker

Diagnose

Behandling

Å leve med inkontinens

Vil du vite mer?

Urininkontinens hos menn

Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2013; 189: S93-S101. 

Schrӧder A. et al. European Association of Urology. Guidelines on urinary incontinence 2010. 

Bettez M, Tu le M, Carlson K, et al. 2012 update: guidelines for adult urinary incontinence collaborative consensus document for the canadian urological association. Can Urol Assoc J 2012; 6: 354-63. 

Abrams P, Cardozo L, Fall M, Griffiths D, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49. 

Offermans MP, Du Moulin MF, Hamers JP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn 2009; 28: 288-94. 

Shamliyan TA, Wyman JF, Ping R, et al. Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol 2009; 11: 145-65. 

Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=10411052[uid]

Catalona WJ, Carvalhal GF, Mager DE, Smith DS . Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433. pmid:10411052 

Herschorn S, Bruschini H, Comiter C, et al. Surgical treatment of stress incontinence in men. Neurourol Urodyn 2010; 29: 179-90. 

JY,Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20. 

Irwin DE, Milsom I, Reilly K, Hunskaar S, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 2008; 5: 2904-10. 

Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009; 181: 710-16. 

Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007; 178: 395-401. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=19854479[uid]

Tennstedt SL, Chiu GR, Link CL, et al. The effects of severity of urine leakage on quality of life in Hispanic, white, and black men and women: the Boston community health survey. Urology 2010; 75: 27. pmid:19854479 

Fujimura T, Kume H, Nishimatsu H, et al. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. BJU Int 2012; 109: 1512-6. 

McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am J Med 2005; 118: 1331-9. 

Lee SW, Doo SW, Yang WJ, Song YS. Importance of relieving the most bothersome symptom for improving quality of life in male patients with lower urinary tract symptoms. Urology 2012; 80: 684-7. 

--&gt; http://dx.doi.org/10.1007/s11255-013-0509-9

Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014 ;46(1):275-84. doi: 10.1007/s11255-013-0509-9. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30467131[uid]

Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018. PMID: 30467131 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=29699858[uid]

Kelleher C, Hakimi Z, Zur R et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018 Sep;74(3):324-333. Epub 2018 Apr 23. PMID: 29699858. 

--&gt; http://www3.interscience.wiley.com/cochrane/mainSearch?mode=startsearch&amp;Query1=Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults&amp;zones1=article-title&amp;opt1=AND&amp;Query2=&amp;zones2=article-title&amp;opt2=AND&amp;Query3=&amp;zones3=author&amp;opt3=AND&amp;Query4=&amp;zones4=abstract&amp;opt4=AND&amp;Query5=&amp;zones5=keywords&amp;products=all&amp;unitstatus=none&amp;FromYear=&amp;ToYear=&amp;x=22&amp;y=13

Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003193. DOI: 10.1002/14651858.CD003193.pub4. Accessed 13 April 2021 

--&gt; http://www3.interscience.wiley.com/cochrane/mainSearch?mode=startsearch&amp;Query1=Botulinum toxin injections for adults with overactive bladder syndrome&amp;zones1=article-title&amp;opt1=AND&amp;Query2=&amp;zones2=article-title&amp;opt2=AND&amp;Query3=&amp;zones3=author&amp;opt3=AND&amp;Query4=&amp;zones4=abstract&amp;opt4=AND&amp;Query5=&amp;zones5=keywords&amp;products=all&amp;unitstatus=none&amp;FromYear=&amp;ToYear=&amp;x=22&amp;y=13

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD005493. DOI: 10.1002/14651858.CD005493.pub3. Accessed 13 April 2021. 

Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol 2008; 53: 53-9. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30183466[uid]

Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol 2018; 36: 3251. pmid: 30183466 

Anderson CA, Omar MI, Campbell SE, et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2015 Jan 20;1:CD001843. 

Bauer RM, Gozzi C, Hübner W, et al. Contemporary management of postprostatectomy incontinence. Eur Urol 2011; 59: 985-96. 

Welk BK, Herschorn S. The male sling for post-prostatectomy urinary incontinence: a review of contemporary sling designs and outcomes. BJU In 2012; 109: 328-44. 

Bauer RM, Bastian PJ, Gozzi C, Stief CG. Postprostatectomy incontinence: all about diagnosis and management. Eur Urol 2009; 55: 322-33. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26845050[uid]

Suarez OA, McCammon KA. The Artificial Urinary Sphincter in the Management of Incontinence. Urology 2016; 92: 14. pmid:26845050 

Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29: 213-40. 

Murray S, Lemack GE. Overactive bladder and mixed incontinence. Curr Urol Rep 2010; 11: 385-92. 

Sacco E, Bientinesi R, Marangi F, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int 2012; 110: E837-44. 

Trost L, Elliott DS. Male stress urinary incontinence: a review of surgical treatment options and outcomes. Adv Urol 2012; 2012: 1-13. 

Eden CG, Arora A, Hutton A. Cancer control, continence, and potency after laparoscopic radical prostatectomy beyond the learning and discovery curves. J Endourol 2011; 25: 815-9. 

Treiyer A, Anheuser P, Bütow Z, Steffens J. A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy. J Urol 2011; 185: 1681-5. 